A novel multilevel statistical method for the study of the relationships between multireceptorial binding affinity profiles and in vivo endpoints

Molecular Pharmacology

Volumn 77, Issue 2, 2010, Pages 149-158

  Selent, Jana ^a   Bauer Mehren, Anna ^a   López, Laura ^a   Loza, María Isabel ^b   Sanz, Ferran ^a   Pastor, Manuel ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DOPAMINE RECEPTOR; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MELPERONE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ADVERSE OUTCOME; ARTICLE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; EXPERIMENTAL MODEL; HUMAN; HYDROPHOBICITY; HYPERGLYCEMIA; IN VIVO STUDY; METABOLIC DISORDER; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIDE EFFECT; STATISTICAL MODEL; WEIGHT GAIN;

AMINO ACID SEQUENCE; ANTIPSYCHOTIC AGENTS; BINDING SITES; ENDPOINT DETERMINATION; LIGANDS; MODELS, CHEMICAL; MODELS, STATISTICAL; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 74549202822     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060103     Document Type: Article

References (29)

1. Altar CA, Vawter MP, and Ginsberg SD (2009) Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology 34:18-54.
2. Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, and Tierney WM (2004) Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 19:1200-1205.
3. Filizola M and Weinstein H (2005) The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J 272:2926-2938.
4. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93-97.
5. Gottfries J (2006) The drug designer's guide to selectivity. Chemometrics Intellig Lab Syst 83:148-156.
6. Gurevich VV and Gurevich EV (2008) How and why do GPCRs dimerize? Trends Pharmacol Sci 29:234-240.
7. Hwa J, Gaivin R, Porter JE, and Perez DM (1997) Synergism of constitutive activity in alpha 1-adrenergic receptor activation. Biochemistry 36:633-639.
8. Kim SF, Huang AS, Snowman AM, Teuscher C, and Snyder SH (2007) From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104:3456-3459.
9. Kobilka B (2004) Agonist binding: a multistep process. Mol Pharmacol 65:1060-1062.
10. Kota P, Reeves PJ, Rajbhandary UL, and Khorana HG (2006) Opsin is present as dimers in COS1 cells: identification of amino acids at the dimeric interface. Proc Natl Acad Sci U S A 103:3054-3059.
11. Lange JH, Reinders JH, Tolboom JT, Glennon JC, Coolen HK, and Kruse CG (2007) Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. J Med Chem 50:5103-5108.
12. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, and Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117.
13. Liu KG and Robichaud AJ (2009) 5-HT6 antagonists as potential treatment for cognitive dysfunction. Drug Dev Res 70:145-168.
14. Lu ZL and Hulme EC (1999) The functional topography of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis. J Biol Chem 274:7309-7315.
15. Millan MJ, Dekeyne A, and Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955.
16. O'Neill MF (2005) Unusual suspect for antipsychotic-induced diabetes. Drug Discov Today 10:1338-1338.
17. Porter JE, Hwa J, and Perez DM (1996) Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 271:28318-28323.
18. Reynolds GP, Hill MJ, and Kirk SL (2006) The 5-HT2C receptor and antipsychoticinduced weight gain-mechanisms and genetics. J Psychopharmacol 20:15-18.
19. Reynolds GP, Templeman LA, and Zhang ZJ (2005) The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 29:1021-1028.
20. Roth BL, Meltzer HY, and Khan N (1998) Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv Pharmacol 42:482-485.
21. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
22. Selent J, López L, Sanz F, and Pastor M (2008) Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new beta2 adrenergic receptor template. ChemMedChem 3:1194-1198.
23. Silvestre JS and Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27:289-304.
24. Surgand JS, Rodrigo J, Kellenberger E, and Rognan D (2006) A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62:509-538.
25. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, and Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623.
26. Wang XS, Tang H, Golbraikh A, and Tropsha A (2008) Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F. J Chem Inf Model 48:997-1013.
27. Waters ML (2002) Aromatic interactions in model systems. Curr Opin Chem Biol 6:736-741.
28. Wold S, Esbensen K, and Geladi P (1987) Principal component analysis. Chemometrics Intell Lab Syst 2:37-52.
29. Wold S, Sjöström M, and Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemometrics Intell Lab Syst 58:109-130